High-Purity Tirzepatide Side-Chain Intermediates Synthesis: Securing the Critical Link in Peptide Manufacturing
Publish Time:
2025-08-20
Tirzepatide, as a highly regarded GLP-1 class drug, relies on the efficient synthesis of key side chain intermediates for stable production. The synthesis process of side chain intermediates is not only a core step in the production process of Tirzepatide but also has a decisive impact on the stability of drug supply, quality safety, and clinical accessibility.
Tirzepatide Structural Formula
Stable Supply: Synthesis of Side Chain Intermediates Ensures Continuity of Drug Production
The standardized synthesis of Tirzepatide side chain intermediates is an important foundation for ensuring the continuous supply of upstream raw materials. By establishing a mature intermediate synthesis system, the risk of raw material shortages in the production process can be effectively avoided, providing stable support for the large-scale production of Tirzepatide, thereby responding promptly to the clinical demand for this drug in the market and ensuring the continuity of medication for patients.
Quality Control: The Synthesis Process Empowers Drug Safety and Efficacy
In the synthesis process of Tirzepatide side chain intermediates, multi-dimensional quality control measures (such as key step detection, purity analysis, impurity monitoring, etc.) can achieve full traceability of quality. This strict quality control model ensures that key indicators such as the physicochemical properties and structural integrity of intermediates meet pharmaceutical standards, laying the foundation for the quality stability of the final Tirzepatide product, thereby enhancing the clinical efficacy and safety of the drug.
Process Optimization: Cost Reduction and Efficiency Improvement Enhance Drug Accessibility
By optimizing the synthesis process of Tirzepatide side chain intermediates through technical breakthroughs, production efficiency can be significantly improved—such as shortening reaction cycles, increasing raw material conversion rates, and reducing by-product generation. The reduction in production costs brought about by process optimization can directly promote the rationalization of the terminal price of Tirzepatide, allowing more patients in need of such drug treatment to afford it, thus expanding the clinical beneficiary population of the drug.
Synthesis Relevant side chain intermediates required for Tirzepatide (Manufacturer: Guangzhou Congen Pharmatec Co.,Ltd.）:
| Serial Number | Product Name | CAS Number |
| 1 | 20-(tert-butoxy)-20-oxoicosanoic acid | 683239-16-9 |
| 2 | tBuO-C20-L-Glu-OtBu | 1119061-70-9 |
| 3 | tBuO-C20-L-Glu(AEEA-AEEA-OH)-OtBu | 1188328-37-1 |
| 4 | Fmoc-L-Lys[tBuO-C20-L-Glu(AEEA-AEEA)-OtBu]-OH | 2915356-76-0 |
| 5 | Fmoc-Glu(OtBu)-Aib-OH | 866044-63-5 |
| 6 | Tirzepatide Frag AA30-39 | 2656383-23-0 |
| 7 | Tirzepatide Frag AA22-29 | 2461524-68-3 |
| 8 | Tirzepatide Frag AA15-21 | 2656383-24-1 |
| 9 | Tirzepatide Frag AA1-14 | 2656383-25-2 |
| 10 | Fmoc-Ile-Aib-OH | 2171139-20-9 |
| 11 | Fmoc-Tyr(tBu)-Aib-OH | 2645414-22-6 |
| 12 | Boc-Tyr(tBu)-Aib-Glu(OtBu)-Gly-OH | 2682040-93-1 |
Relevant Information
undefined
